Literature DB >> 11472425

Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages.

M Hausmann1, T Spöttl, T Andus, G Rothe, W Falk, J Schölmerich, H Herfarth, G Rogler.   

Abstract

Macrophages play a central role during the pathogenesis of inflammation. In normal intestinal mucosa surface expression of typical macrophage markers such as CD14, CD16, CD11b or T-cell co-stimulatory molecules such as CD80 or CD86 is low indicating anergy and low pro-inflammatory activity of these cells. During inflammatory bowel disease (IBD) the mucosa is invaded by a population of macrophages displaying these markers, secreting higher cytokine levels and representing an activated cell population. CD33(+) cells (macrophages) were isolated from normal and Crohn's disease mucosa and mRNA was isolated by polyT magnetic beads. A subtractive screening was performed subtracting mRNA from normal macrophages from those of Crohn's disease macrophages. Oxidative burst activity was determined by flow cytometry. Seventy clones were obtained by the subtractive mRNA screening. Sequencing showed > 99% homology to mRNA of monocyte chemoattractant protein-1 (MCP-1) for three clones. Five clones obtained by subtraction revealed > 99% homology to mRNA of cytochrome b (subunit gp91). Differential expression of the cytochrome b subunit gp91 and the cytosolic NADPH oxidase subunit p67 was confirmed by RT-PCR and 'virtual' Northern blots. The fluorescence ratio of stimulated versus unstimulated cells was 0.9 +/- 0.16 in control macrophages indicating a lack of oxidative burst activity. In Crohn's disease this ratio was significantly increased to 1.80 +/- 0.8 (P = 0.004) confirming the molecular data. In conclusion NADPH oxidase mRNA is down-regulated or absent in macrophages from normal mucosa correlating with a lack of oxidative burst activity. In IBD macrophage-oxidative burst activity is increased and NADPH oxidase mRNA induced. Inhibition of NADPH oxidase could be a new therapeutical target in IBD and reduce mucosal tissue damage in active IBD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472425      PMCID: PMC1906098          DOI: 10.1046/j.1365-2249.2001.01567.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease.

Authors:  M C Allison; S Cornwall; L W Poulter; A P Dhillon; R E Pounder
Journal:  Gut       Date:  1988-11       Impact factor: 23.059

2.  Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes.

Authors:  G Rothe; A Oser; G Valet
Journal:  Naturwissenschaften       Date:  1988-07

3.  The structure of the colonic mucosa. The epithelium and subepithelial reticulohistiocytic complex.

Authors:  W L Donnellan
Journal:  Gastroenterology       Date:  1965-11       Impact factor: 22.682

4.  Isolation and preliminary characterization of human intestinal macrophages.

Authors:  J P Golder; W F Doe
Journal:  Gastroenterology       Date:  1983-04       Impact factor: 22.682

5.  T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa.

Authors:  G Rogler; M Hausmann; T Spöttl; D Vogl; E Aschenbrenner; T Andus; W Falk; J Schölmerich; V Gross
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-10       Impact factor: 2.566

6.  Interleukin 2 receptor expression by macrophages in inflammatory bowel disease.

Authors:  Y R Mahida; S Patel; K Wu; D P Jewell
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

7.  Isolation and functional characterization of human intestinal mucosal lymphoid cells.

Authors:  D M Bull; M A Bookman
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

8.  Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000.

Authors:  C A Parkos; R A Allen; C G Cochrane; A J Jesaitis
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

9.  Effects of various inhibitors of arachidonic acid oxygenation on macrophage superoxide release and tumoricidal activity.

Authors:  R M Schultz; S K Nanda; M G Altom
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

10.  Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80.

Authors:  S H Lee; P M Starkey; S Gordon
Journal:  J Exp Med       Date:  1985-03-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

2.  Role of soluble factors and three-dimensional culture in in vitro differentiation of intestinal macrophages.

Authors:  Tanja Spoettl; Martin Hausmann; Katrin Menzel; Heidi Piberger; Hans Herfarth; Juergen Schoelmerich; Frauke Bataille; Gerhard Rogler
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

3.  Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes.

Authors:  T Spoettl; M Hausmann; M Herlyn; M Gunckel; A Dirmeier; W Falk; H Herfarth; J Schoelmerich; G Rogler
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 4.  Intestinal antigen-presenting cells in mucosal immune homeostasis: crosstalk between dendritic cells, macrophages and B-cells.

Authors:  Elizabeth R Mann; Xuhang Li
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease.

Authors:  K Schreiter; M Hausmann; T Spoettl; U G Strauch; F Bataille; J Schoelmerich; H Herfarth; W Falk; G Rogler
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

6.  Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.

Authors:  K Menzel; M Hausmann; F Obermeier; K Schreiter; N Dunger; F Bataille; W Falk; J Scholmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

7.  In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis.

Authors:  M Hausmann; F Obermeier; D H Paper; K Balan; N Dunger; K Menzel; W Falk; J Schoelmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

8.  NOD2 status and human ileal gene expression.

Authors:  Christina M Hamm; Melissa A Reimers; Casey K McCullough; Elizabeth B Gorbe; Jianyun Lu; C Charles Gu; Ellen Li; Brian K Dieckgraefe; Qingqing Gong; Thaddeus S Stappenbeck; Christian D Stone; David W Dietz; Steven R Hunt
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

Review 9.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

10.  Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation.

Authors:  Jana Fritsche; Alexandra Müller; Martin Hausmann; Gerhard Rogler; Reinhard Andreesen; Marina Kreutz
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.